tuneTypical Dose
250-500 mg standardized extract, 1-2 times daily
Botanical
Passiflora incarnata
tuneTypical Dose
250-500 mg standardized extract, 1-2 times daily
watchEffect Window
Sleep effects may be noticeable within 1-3 nights. Sustained anxiety reduction may take 1-2 weeks to fully develop.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Passionflower has limited but real evidence for anxiety reduction and sleep-quality support, with a generally favorable tolerability profile at standard doses.
Passionflower contains flavonoids (chrysin, apigenin, vitexin) and other constituents that modulate GABAergic signaling. A small active-comparator trial suggested it could approach oxazepam for generalized-anxiety symptom relief with less work-impairment burden, and additional trials support sleep-quality improvement. The safety profile is generally favorable at standard doses, with sedation as the main practical limiter. It is a credible but still modest-evidence botanical for mild anxiety and sleep-onset difficulty, not a high-certainty substitute for standard anxiolytics.
Passionflower flavonoids (chrysin, apigenin) act as partial agonists at the GABA-A benzodiazepine site, producing anxiolysis with limited sedation and low dependence risk. The extract also inhibits GABA transaminase, increasing synaptic GABA availability. Additional interactions with opioid and serotonin receptors may contribute to its calming and mood-modulating effects.
Article
Passiflora incarnata, commonly called passionflower or maypop, is a perennial climbing vine native to the southeastern United States and Central America. It has been used in traditional medicine for centuries as a sedative and anxiolytic, and it was listed in the US National Formulary from 1916 through the 1930s as a plant-based sedative.
Modern supplement marketing often groups passionflower with general "calming herbs" alongside chamomile, lemon balm, and lavender. While it shares the calming category, passionflower has a more specific pharmacological profile and stronger clinical evidence than most of its shelf neighbors. The head-to-head comparison with oxazepam (a benzodiazepine) is unusual for a botanical supplement and gives passionflower a credibility edge that most herbal anxiolytics lack.
That said, the evidence base is still modest by pharmaceutical standards. The landmark anxiety trial had a small sample size, and the sleep studies are limited in number. Passionflower is best understood as a well-tolerated, mildly to moderately effective botanical anxiolytic with the strongest evidence for situational anxiety and sleep onset difficulty.
Passionflower contains several flavonoids with demonstrated affinity for GABA-A receptors, most notably chrysin and apigenin. Chrysin binds to the benzodiazepine site on GABA-A receptors and acts as a partial agonist, producing anxiolytic effects with lower maximal efficacy than full benzodiazepine agonists. This partial agonist profile is pharmacologically advantageous because it produces anxiolysis with a lower ceiling for sedation, motor impairment, and dependence compared to full agonists.1
Apigenin, another flavonoid present in passionflower, also binds the benzodiazepine site but with different affinity and selectivity. The combination of multiple flavonoids with overlapping but distinct GABA-A receptor interactions may produce a broader, more balanced anxiolytic effect than any single compound alone.
Beyond direct receptor modulation, passionflower extracts inhibit GABA transaminase (GABA-T), the enzyme responsible for breaking down GABA in the synaptic cleft. By slowing GABA degradation, passionflower increases the effective concentration and duration of endogenous GABA signaling. This mechanism is complementary to the direct receptor modulation and may explain why whole passionflower extracts produce stronger effects than isolated flavonoids alone.2
Some research suggests passionflower constituents interact with opioid receptors and serotonin receptors, though these effects are less well-characterized than the GABAergic mechanisms. The opioid receptor interaction may contribute to the subjective sense of relaxation and well-being reported by users, while serotonergic effects could contribute to mood-modulating properties.
The multi-target pharmacology is typical of complex botanical extracts and makes it difficult to attribute effects to any single compound. This is both a strength (broader therapeutic profile) and a limitation (harder to standardize and dose precisely).
The most important clinical study of passionflower is Akhondzadeh et al. (2001), a 4-week double-blind randomized trial comparing passionflower extract (45 drops/day of liquid extract) to oxazepam (30 mg/day) in 36 patients with generalized anxiety disorder (GAD).3
The results were remarkable for a botanical:
The clinical significance of this finding is that passionflower produced comparable anxiety relief to a benzodiazepine in diagnosed GAD patients while causing less functional impairment. The tradeoff was slower onset.
Limitations are important to acknowledge. The sample size was small (36 patients). The trial duration was 4 weeks. Oxazepam 30 mg/day is a low to moderate benzodiazepine dose. There has been no large-scale replication of this specific comparison. Despite these caveats, this remains one of the strongest single-trial results for any botanical anxiolytic.
Several smaller trials have tested passionflower for situational anxiety, particularly before surgery or dental procedures. Movafegh et al. (2008) found that 500 mg of passionflower extract taken 90 minutes before surgery reduced preoperative anxiety scores without increasing sedation or delaying recovery from anesthesia.
This application, using passionflower as a one-time or short-course anxiolytic for defined stressful events, may be its most practical clinical niche. The GABAergic mechanism produces genuine anxiolysis without the performance impairment and dependence risk associated with prescribing benzodiazepines for occasional use.
Ngan and Conduit (2011) conducted a double-blind, placebo-controlled trial examining passionflower tea consumed nightly for one week. They found significant improvements in subjective sleep quality as measured by sleep diary ratings, though polysomnographic (objective) sleep measures showed more modest changes.4
The improvement in subjective sleep quality is consistent with the anxiolytic mechanism. People whose sleep difficulty stems from racing thoughts, rumination, or generalized tension at bedtime are the most likely to benefit. Passionflower is not a strong sedative-hypnotic and is unlikely to help with sleep problems driven by circadian disruption, sleep apnea, or other non-anxiety-related causes.
Additional sleep research has shown that passionflower extract improves total sleep time and sleep efficiency in individuals with insomnia symptoms, though sample sizes remain small.
The Akhondzadeh trial lasted 4 weeks. Whether passionflower maintains its anxiolytic efficacy with longer use is unknown. Tolerance to GABAergic effects is a theoretical concern (it occurs with benzodiazepines), though the partial agonist profile of passionflower flavonoids suggests tolerance development may be slower or less complete.
Some preclinical studies suggest antidepressant-like effects of passionflower constituents, but human evidence for depression is essentially absent. Do not use passionflower as a primary treatment for depressive disorders.
A few small studies have tested passionflower in combination with other botanicals for ADHD symptoms, with mixed results. The evidence is too preliminary and confounded to draw meaningful conclusions.
The generalized anxiety data does not necessarily extend to other anxiety subtypes. Panic disorder and specific phobias may not respond to the same GABAergic modulation that helps GAD, and no adequate trials exist in these populations.
Appel et al. (2011) conducted a systematic review of passionflower safety and tolerability data across clinical trials and pharmacovigilance reports. Their conclusion was that Passiflora incarnata has a favorable safety profile at recommended doses, with no serious adverse events reported in clinical trials.5
The most common side effects are:
No hepatotoxicity signal has been identified for Passiflora incarnata specifically, though one case report of liver injury was associated with a multi-herb product containing a different Passiflora species (P. alata). Species identification matters when selecting products.
Passionflower has not been adequately studied during pregnancy and should be avoided. Some Passiflora species contain harmala alkaloids (harmine, harmaline) that have uterotonic properties. While P. incarnata contains only trace amounts of these alkaloids, the precautionary principle applies.
The primary interaction concern is additive sedation when combined with other CNS depressants:
Passionflower may also interact with anticoagulants due to coumarin content in some preparations, though clinically significant bleeding events have not been documented.
The harmala alkaloid content (trace in P. incarnata, higher in other species) has theoretical MAO inhibitory activity. At the trace levels present in standard P. incarnata extracts, this is unlikely to be clinically significant, but combining very high doses with MAOIs or tyramine-rich foods is theoretically inadvisable.6
Dosing varies considerably between preparations:
A practical protocol:
For sleep support, take 30-60 minutes before bedtime. For daytime anxiety, morning and/or early afternoon dosing avoids bedtime sedation stacking with natural circadian sleep drive.
Tea preparations are traditional and well-studied but difficult to standardize. Capsule extracts offer more consistent dosing. Look for products standardized to flavonoid content (particularly vitexin or total flavonoids) and verified as Passiflora incarnata (not P. alata, P. caerulea, or other species with different alkaloid profiles).
Combination products with valerian are common for sleep applications. The combination has some supporting evidence but makes it impossible to attribute effects to either herb individually.
Passionflower is one of the most credible botanical anxiolytics available. The head-to-head comparison with oxazepam is a stronger clinical data point than most herbal supplements can claim, and the safety profile is clean enough to make it a reasonable first-line botanical option for mild to moderate situational anxiety and sleep onset difficulty.
What it is good for:
What it is not good for:
If you want a botanical approach to anxiety that has more clinical evidence than most alternatives and is well-tolerated enough for daily use, passionflower deserves consideration. Use a standardized Passiflora incarnata extract, start at a moderate dose, and evaluate effects over 1-2 weeks for anxiety and 3-5 nights for sleep.
Chrysin and apigenin from passionflower bind the benzodiazepine site on GABA-A receptors as partial agonists, producing anxiolysis with a lower ceiling for sedation and dependence compared to full benzodiazepine agonists.
↩Passionflower extracts inhibit GABA transaminase, slowing GABA breakdown and increasing effective synaptic GABA concentration, complementing the direct receptor modulation by flavonoid constituents.
↩Akhondzadeh et al. (2001) found passionflower extract comparable to oxazepam 30 mg/day for GAD over 4 weeks, with significantly less job performance impairment but slower onset of anxiolytic effects.
↩Ngan and Conduit (2011) demonstrated significant improvements in subjective sleep quality with nightly passionflower tea over one week in a double-blind, placebo-controlled trial.
↩Appel et al. (2011) systematically reviewed passionflower safety data and found a favorable tolerability profile at recommended doses with no serious adverse events in clinical trials.
↩Passiflora incarnata contains trace harmala alkaloids with theoretical MAO inhibitory activity, though levels are too low for clinical significance at standard doses. Higher-alkaloid species (P. alata) should not be substituted.
↩Outcomes
Safety
Evidence
Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001;26(5):363-367. doi:10.1046/j.1365-2710.2001.00367.x. PMID:11679026.
Population: Outpatients diagnosed with generalized anxiety disorder using DSM-IV criteria.
Dose protocol: 45 drops/day passionflower liquid extract vs oxazepam 30 mg/day for 4 weeks
Key findings: Passionflower was as effective as oxazepam for reducing HAM-A scores in GAD patients over 4 weeks, with significantly less impairment of job performance. Onset was slower (week 2 vs week 1).
This pilot active-comparator anxiety trial is the strongest single reason passionflower still has credibility as an anxiolytic botanical. Thirty-six adults with GAD were randomized to Passiflora incarnata extract or oxazepam for 4 weeks. Both groups improved, with no significant difference at trial end, but oxazepam acted faster and caused more job-performance impairment. The study supports a real calming effect, but it was small, short, and compared against an active drug rather than placebo, so it should be treated as supportive rather than definitive evidence.
Ngan A, Conduit R. A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passionflower) herbal tea on subjective sleep quality. Phytother Res. 2011;25(8):1153-1159.
Population: 41 healthy adults aged 18-35
Dose protocol: Passionflower tea (2g dried herb) nightly for 7 nights
Key findings: Significant improvement in subjective sleep quality vs placebo. Polysomnographic measures showed more modest objective improvements. Short duration limits interpretation.
A double-blind, placebo-controlled study in 41 healthy adults examining the effects of passionflower (Passiflora incarnata) herbal tea on sleep quality. Participants consuming passionflower tea before bed showed significantly improved subjective sleep quality scores compared to those receiving placebo tea. The findings support the traditional use of passionflower as a mild sleep aid in healthy populations.
Appel K et al. Modulation of the gamma-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytother Res. 2011;25(6):838-843.
Population: In vitro cell-based assays examining GABA receptor modulation
Dose protocol: Systematic review of safety and tolerability data
Key findings: Favorable safety profile at recommended doses. No serious adverse events in clinical trials. Drowsiness is the primary dose-limiting effect.
An in vitro study examining the GABAergic mechanisms of Passiflora incarnata. The research demonstrated that passionflower extracts modulate the GABA system through multiple pathways, primarily through flavonoid constituents such as chrysin and apigenin acting on GABA-A receptors. These findings provide a mechanistic basis for the anxiolytic and sedative properties traditionally attributed to passionflower.
Lee J, Jung HY, Lee SI, Choi JH, Kim SG. Effects of Passiflora incarnata Linnaeus on polysomnographic sleep parameters in subjects with insomnia disorder: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol. 2020;35(1):29-35. doi:10.1097/YIC.0000000000000291. PMID:31714321.
Population: Adults with insomnia disorder.
Dose protocol: Passiflora incarnata extract vs placebo in 110 insomnia patients with polysomnography
Key findings: Total sleep time increased significantly (+23 min vs placebo, P=0.049). Sleep efficiency and WASO improved numerically but did not reach significance.
Notes: Largest passionflower sleep trial with objective polysomnographic measures.
This double-blind randomized placebo-controlled trial tested Passiflora incarnata in 110 adults with insomnia disorder using polysomnographic measurement. Total sleep time increased significantly in the passionflower group compared to placebo (+23.05 minutes vs -0.16 minutes, P=0.049). Sleep efficiency and wake after sleep onset improved numerically in the passionflower group but did not reach statistical significance versus placebo. This is one of the largest and most rigorous passionflower sleep studies, providing objective polysomnographic evidence for a modest but real sleep-extending effect.
Janda K, Wojtkowska K, Jakubczyk K, Antoniewicz J, Skonieczna-Zydecka K. Passiflora incarnata in Neuropsychiatric Disorders-A Systematic Review. Nutrients. 2020;12(12):3894. doi:10.3390/nu12123894. PMID:33352740.
Population: Patients with neuropsychiatric conditions across nine included clinical trials.
Dose protocol: Systematic review of 9 RCTs of Passiflora incarnata in neuropsychiatric disorders
Key findings: Majority of studies reported reduced anxiety levels. No adverse effects including memory loss or psychometric impairment observed. Effects less pronounced in mild anxiety.
Notes: Broadens the evidence base beyond single trials.
This systematic review examined nine randomized clinical trials of Passiflora incarnata for neuropsychiatric conditions. The majority of studies reported reduced anxiety levels following passionflower administration, though effects were less pronounced in mild anxiety cases. Notably, no adverse effects including memory loss or psychometric function impairment were observed across trials. The review supports passionflower as a helpful intervention for some neuropsychiatric symptoms, particularly anxiety, with a favorable safety profile.